secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001654954-23-001434
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics raises ~$15.6M in public offering of common stock and warrants
--------------------------------------------------------------------------------

- Priced 8,666,666 shares (or pre-funded warrants) plus 17,333,332 warrants at $1.80/unit.
- Gross proceeds ~$15.6M; net proceeds ~$14.1M after fees and expenses.
- Warrants exercisable at $2.25/share, expire 5 years from issuance.
- Proceeds to fund Phase 3 trial of imatinib for PAH and levosimendan for PH-HFpEF.
- Offering closed Feb 7, 2023; post-closing shares outstanding 9,265,099.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/0001654954-23-001434-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423001434/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-001434

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer